Dosing

Dosing Calculator

By using the slider bar below, you can calculate the number of vials and volume of Vyxeos® Liposomal required per infusion to treat your patients.

Drag the blue button across the white slider bar in order to select your patient’s body surface area (m2). The body surface area variable will automatically snap to the nearest recognised figure. The dosing calculator will then calculate and return the corresponding induction and consolidation figures needed below:

Body surface area (m2)
INDUCTION (44/100 mg)/m2
Number of vials
Volume to withdraw (mL)*
CONSOLIDATION (29/65 mg)/m2
Number of vials
Volume to withdraw (mL)*

Induction: Days 1, 3 and 5. Second induction and consolidation: Days 1 and 3.1
For more information, visit our page on the 
Administration, Schedule and Infusion time of Vyxeos Liposomal.

*Rounded to the nearest 0.1 mL

Calculating Vyxeos Liposomal Dose

To determine the dose and number of vials you will need for each patient, calculate the volume of reconstituted Vyxeos Liposomal required using the following formula:1

Dose of daunorubicin (mg/m2) X patient’s body surface area (m2)
2.2 mg/mL
= mL volume required
  • Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine.1
  • After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine, encapsulated in liposomes in a fixed combination in a 1:5 molar ratio.1

For more information about preparing and administering Vyxeos Liposomal, visit our Preparation and Instructions page for a step-by-step walkthrough on how to prepare and administer Vyxeos Liposomal.

References

  1. Vyxeos Liposomal – Summary of Product Characteristics, October 2019

 

ADVERSE EVENTS REPORTING

 

Reporting of side effects: Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via their national reporting system. Adverse events should also be reported to Jazz Pharmaceuticals by email: AEreporting@jazzpharma.com or by fax to +44 (0) 1865 598765

 

INT-VYX-2000063 | June 2020